Lisa Cook sues Trump over firing attempt, emergency hearing set
Richard Klausner, a director at Lyell Immunopharma , Inc. (NASDAQ:LYEL), recently acquired 158,000 shares of the company’s common stock. The shares were purchased on March 14 at a weighted average price of $0.6009, with the total transaction valued at approximately $94,942. The purchase comes as LYEL shares trade near their 52-week low of $0.48, having declined nearly 28% in the past week alone. InvestingPro data shows the stock has fallen about 69% over the past six months.
This acquisition increased Klausner’s total direct and indirect holdings to 3,812,199 shares. The shares were acquired through The Klausner Family Revocable Trust and other trusts, as detailed in the SEC filing footnotes. Want deeper insights into insider trading patterns and 12 additional key metrics for LYEL? Unlock full access with InvestingPro.
Lyell Immunopharma, based in South San Francisco, focuses on developing innovative therapies in the pharmaceutical sector. With a market capitalization of $143.48 million, the company maintains strong liquidity with a current ratio of 7.06, though InvestingPro analysis indicates an overall weak financial health score. This transaction reflects Klausner’s continued investment in the company, which operates under the ticker LYEL on the NASDAQ exchange.
In other recent news, Lyell Immunopharma has been notified by Nasdaq regarding non-compliance with the minimum bid price requirement, as its stock closed below $1.00 for 33 consecutive business days. The company has until July 22, 2025, to rectify this by ensuring its stock maintains a closing bid price of at least $1.00 for 10 consecutive business days. If Lyell fails to meet this requirement, it may receive an additional 180 days to comply by transferring to The Nasdaq Capital Market, provided other listing standards are met. Meanwhile, H.C. Wainwright has maintained a Neutral rating on Lyell Immunopharma, with a steady price target of $1.00. The firm highlighted the development of Lyell’s IMPT-314, a dual-targeting CAR-T candidate for large B-cell lymphoma, and is closely monitoring its Phase 1/2 trial results. Analysts are particularly interested in the upcoming data from the second-line setting, expected in mid-2025, and how it compares to existing therapies. The competitive landscape for new CAR-T therapies remains challenging, with existing treatments setting high efficacy benchmarks. Lyell is considering measures such as a reverse stock split to address the Nasdaq compliance issue, although success in regaining compliance is not guaranteed.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.